Optiscan Imaging Ltd (ASX: OIL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Optiscan Imaging Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Optiscan Imaging Ltd (ASX: OIL)
Latest News
Share Market News
Why the OptiScan (ASX:OIL) share price is rocketing 26% today
Share Market News
Why the Optiscan (ASX:OIL) share price is going gangbusters
Share Market News
Why the OptiScan (ASX:OIL) share price is climbing higher
Share Market News
Optiscan (ASX:OIL) share price flat on FDA update
OIL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Optiscan Imaging Ltd
Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States.
OIL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
04 Oct 2024 | $0.17 | $-0.01 | -5.71% | 97,447 | $0.18 | $0.18 | $0.17 |
03 Oct 2024 | $0.18 | $-0.01 | -5.41% | 543,567 | $0.18 | $0.18 | $0.17 |
02 Oct 2024 | $0.19 | $0.00 | 0.00% | 214,237 | $0.19 | $0.19 | $0.18 |
01 Oct 2024 | $0.19 | $-0.01 | -5.13% | 2,894 | $0.19 | $0.19 | $0.19 |
30 Sep 2024 | $0.20 | $0.01 | 5.26% | 44,476 | $0.19 | $0.20 | $0.18 |
27 Sep 2024 | $0.19 | $0.00 | 0.00% | 38,303 | $0.19 | $0.19 | $0.19 |
26 Sep 2024 | $0.19 | $0.00 | 0.00% | 166,062 | $0.19 | $0.19 | $0.17 |
25 Sep 2024 | $0.19 | $-0.01 | -5.13% | 158,221 | $0.19 | $0.19 | $0.19 |
24 Sep 2024 | $0.20 | $0.01 | 5.26% | 170,084 | $0.20 | $0.20 | $0.18 |
23 Sep 2024 | $0.19 | $0.03 | 18.75% | 753,853 | $0.17 | $0.19 | $0.17 |
20 Sep 2024 | $0.16 | $0.01 | 6.45% | 92,860 | $0.16 | $0.17 | $0.16 |
19 Sep 2024 | $0.16 | $0.01 | 6.67% | 16,442 | $0.15 | $0.16 | $0.15 |
18 Sep 2024 | $0.15 | $0.01 | 6.90% | 107,203 | $0.15 | $0.15 | $0.15 |
17 Sep 2024 | $0.15 | $-0.02 | -12.50% | 398,368 | $0.17 | $0.17 | $0.15 |
16 Sep 2024 | $0.16 | $0.00 | 0.00% | 69,845 | $0.16 | $0.16 | $0.16 |
13 Sep 2024 | $0.16 | $0.00 | 0.00% | 66,498 | $0.16 | $0.16 | $0.16 |
12 Sep 2024 | $0.16 | $-0.02 | -11.11% | 61,703 | $0.17 | $0.17 | $0.16 |
11 Sep 2024 | $0.18 | $0.02 | 12.50% | 230,595 | $0.16 | $0.18 | $0.16 |
10 Sep 2024 | $0.16 | $-0.01 | -6.06% | 15,031 | $0.16 | $0.16 | $0.16 |
09 Sep 2024 | $0.17 | $0.02 | 13.33% | 171,640 | $0.16 | $0.17 | $0.16 |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Ronnie (Ron) Song | Non-Executive Director | Feb 2021 |
Mr Song had a 25 year business career in Australia before being headhunted in 1999 to assist in expanding a European motor vehicle franchise in Singapore. In a short time, Ron assisted in developing the franchise into a profitable business. He expanded and developed a second company in the motor vehicle industry, Premium Automobiles Pty Ltd, where he was the Managing Director for seven years before advising and developing a premier Singaporean wellness company, Fabulous Image Lifestyle, which was successfully sold to a pan-Asian operator. He is Member of Risk Committee.
|
Mr Robert Cooke | Non-Executive ChairmanNon-Executive Director | Apr 2021 |
Mr Cooke is the former Managing Director & CEO of Healthscope, one of Australia's leading private hospital, medical centre and pathology operators between 2010 and 2017. He has a 40+ year career in the health industry, his experience spans to executive leadership of publicly listed and privately owned healthcare companies, and a management of private and public hospitals in Australia, Asia and the UK. He is Member of Risk Committee.
|
Ms Karen Borg | Non-Executive Director | Jul 2021 |
Ms Borg is a experienced senior executive, who has held global leadership positions in multiple sectors, including medical devices and technology, aged care, consumer products and government. Karen's background is in commercial management, global marketing and sales and government policy. Karen was Chief Executive Officer, Catholic Healthcare Ltd and prior to this was CEO Healthdirect and the inaugural Chief Executive for Jobs for NSW. Her international healthcare experience includes President (Asia Pacific and Middle East) of ResMed Inc and several senior roles with Johnson & Johnson Medical Devices companies, including Global Vice President (based in USA). She was a NSW finalist for Telstra Businesswoman of the Year 2017.She is Chair of Risk Committee.
|
Professor Camile Farah | Chief Executive OfficerManaging Director | May 2021 |
Mr Farah is a executive, academic, researcher and author with 25 years' experience in the healthcare, biotech and medical research sectors. He is dual trained oral clinician and maxillofacial pathologist with appointments at Hollywood Private Hospital, Precision Pathology and Genomics for Life. Professor Farah is a leading Australian expert in oral cancer and precancerous pathology based on his clinical and research having published 250 clinical and scientific articles and a textbook. He is a former Dean and Chief Executive of the Oral Health Centre at the University of Western Australia. He holds an Adjunct Professor title at CQ University and an Honorary Professorial Research Fellowship at the Peter MacCallum Cancer Centre. In addition to managing his own consulting business, he is Executive Director of the Australian Centre for Oral Oncology Research & Education which undertakes cutting edge research in head and neck cancer. He serves as a non-executive director and Honorary Treasurer of the Australian and New Zealand Head and Neck Cancer Society. He is Member of Risk Committee.
|
Mr Sean Gardiner | Non-Executive Director | Jun 2022 |
Mr Gardiner is a Managing Director and Head of Private Investments at the Clermont Group. Prior to joining Clermont, Sean worked at Morgan Stanley, where he spent 20 years in equity research across three locations and in seven different roles. In 2000, he joined the London office covering European Technology and Conglomerate stocks before, in 2005, moving to lead the EEMEA Telecom Services team. In early 2008, Sean transferred to Dubai to setup and manage the MENA Equity Research team. Sean relocated to Singapore in 2010 to oversee and manage the broader Asian research product as well as roll out ASEAN Real Estate coverage. In 2016, he was promoted to Head of ASEAN Research and ASEAN Equity Strategist.
|
Mr Justin Mouchacca | Company Secretary | Dec 2016 |
-
|
Justin Mouchacca | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Peters Investments Pty Ltd | 205,567,445 | 24.62% |
HSBC Custody Nominees (Australia) Limited | 158,872,000 | 19.03% |
Ibsen Pty Ltd (Narula Family Set No.3 A/C) | 38,500,000 | 4.61% |
Citicorp Nominees Pty Limited | 36,026,006 | 4.31% |
Harech Pty Ltd (Porter Super Fund A/C) | 18,934,491 | 2.27% |
Bnp Paribas Noms Pty Ltd (Drp) | 18,146,343 | 2.17% |
Mr Chris Graham & Mrs Diane Graham (C & D Graham S/F A/C) | 13,200,000 | 1.58% |
BNP Paribas Noms Pty Ltd Hub24 Custodial Serv Ltd (DRP A/C) | 9,790,390 | 1.17% |
Dixson Trust Pty Limited | 8,474,270 | 1.01% |
Camile Farah & Marie Martias (Farah & Martias Family A/C) | 8,000,000 | 0.96% |
Sash Pty Ltd (Knezevic Super Fund A/C) | 6,837,964 | 0.82% |
Kebin Nominees Pty Ltd | 6,005,479 | 0.72% |
Ibsen Pty Ltd (Ibsen Superfund A/C) | 5,000,000 | 0.60% |
Mr Alfred J Winklemeier & Mrs Christine E Winklemier | 4,700,000 | 0.56% |
Mr Kah C Lee | 4,688,888 | 0.56% |
Semblance Pty Ltd (Graeme Mutton Retire S/Fund) | 4,470,635 | 0.54% |
D &K Corps Retirement Pty Ltd (D & K Corps Family A/C) | 4,214,816 | 0.50% |
Mr Christopher J Martin | 4,209,448 | 0.50% |
Mr Wally Knezevic | 4,134,260 | 0.50% |
Mr Graeme L Mutton | 3,490,000 | 0.42% |